Medical Letter on the CDC & FDA
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Medical Letter on the CDC & FDA
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Cardiology
European approval granted for drug-eluting stent system
October 23rd, 2005
Angiotech Pharmaceuticals, Inc., (ANPI, ANP) corporate partner Boston Scientific Corp. (BSC) has received CE Mark for its Taxus Liberte paclitaxel-eluting stent system, a drug-eluting stent system. BSC plans to launch the product in European markets and other key CE Mark-dependent international markets immediately. Taxus Liberte was launched earlier this year in select international markets and is expected to launch in the United States in 2006. "We are very pleased to receive European approval for our next-generation drug-eluting stent system," said Paul LaViolette, chief operating officer of Boston Scientific. "The Taxus Liberte stent system is...
Source: Medical Letter on the CDC & FDA (2005-10-23)
|
